Skip to Content
MilliporeSigma
All Photos(2)

Documents

B9061

Sigma-Aldrich

Bicalutamide (CDX)

≥98% (HPLC), powder

Synonym(s):

Casodex, Cosudex, N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C18H14F4N2O4S
CAS Number:
90357-06-5
Molecular Weight:
430.37
MDL number:
MFCD00869971
UNSPSC Code:
12352200
PubChem Substance ID:
329773312
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

storage condition

desiccated
protect from light

solubility

DMSO: >5 mg/mL
H2O: insoluble

originator

AstraZeneca

SMILES string

CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F

InChI

1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

InChI key

LKJPYSCBVHEWIU-UHFFFAOYSA-N

Gene Information

human ... AR(367)

Looking for similar products? Visit Product Comparison Guide

Application

Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate, bladder cancer cell lines and human fetal skeletal muscle cells. It has also been used as a supplement in RPMI 1640 for culturing androgen-independent LNCaP (LNCaP-AI) cell line.

Biochem/physiol Actions

Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardEnvironment
GHS08,GHS09

signalword

Danger

Hazard Classifications

Aquatic Chronic 1 - Carc. 2 - Repr. 1B

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 7

1 of 7

Hydroxyflutamide ≥98% (HPLC)

Sigma-Aldrich

H4166

Hydroxyflutamide

Fenobam ≥98% (HPLC), solid

Sigma-Aldrich

F0430

Fenobam

Abiraterone acetate ≥98% (HPLC)

Sigma-Aldrich

SML1527

Abiraterone acetate

Fulvestrant >98% (HPLC)

Sigma-Aldrich

I4409

Fulvestrant

5α-Dihydrotestosterone (DHT) solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-073

5α-Dihydrotestosterone (DHT) solution

Dutasteride ≥98% (HPLC)

Sigma-Aldrich

SML1221

Dutasteride

Anastrozole ≥98% (HPLC)

Sigma-Aldrich

A2736

Anastrozole

Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth
Zhu YP, et al.
Testing, 6(16), 14488-14488 (2015)
Benoît Boutin et al.
The Prostate, 73(10), 1090-1102 (2013-03-28)
Treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical androgen deprivation. However, it is only temporarily efficient. After a few months or years, the tumor relapses despite the absence of androgenic stimulation: a state referred to as hormone-refractory
S Belikov et al.
Molecular and cellular endocrinology, 365(1), 95-107 (2012-10-16)
Prostate cancer growth depends on androgens. Synthetic antiandrogens are used in the cancer treatment. However, antiandrogens, such as bicalutamide (BIC), have a mixed agonist/antagonist activity. Here we compare the antiandrogenic capacity of BIC to a new antiandrogen, MDV3100 (MDV) or
Androgen receptor antagonist bicalutamide induces autophagy and apoptosis via ULK2 upregulation in human bladder cancer cells
Hao K, et al.
International Journal of Clinical and Experimental Pathology, 10(7), 7603-7615 (2017)
Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells
Antinozzi C, et al.
Journal of Endocrinological Investigation, 40(10), 1133-1143 (2017)
View All Related Papers

Related Content

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service